Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension.

Background: Specific therapy for patients with PAH is associated with good outcomes. Little is known about the effect of this treatment in patients with Cpc-PH (PAPm ≥ 25 mmHg, PAWP > 15 mmHg, DPG ≥ 7 mmHg, and/or PVR > 3 WU). This study evaluates the outcome of treating patients with Cpc-PH using PAH specific therapy.

Metabolic Signatures of Lung Cancer in Sputum and Exhaled Breath Condensate Detected by H Magnetic Resonance Spectroscopy: A Feasibility Study.

Objectives: Lung cancer is one of the most lethal cancers. Currently, there are no biomarkers for early detection, monitoring treatment response, and detecting recurrent lung cancer. We undertook this study to determine if H magnetic resonance spectroscopy (MRS) of sputum and exhaled breath condensate (EBC), as a noninvasive tool, can identify metabolic biomarkers of lung cancer.

Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.

Background: The most effective approaches to escalating advanced therapies in pulmonary arterial hypertension (PAH) are controversial.

Objective: To compare outcomes before and after introducing a target 6 min walk distance (6MWD) treatment strategy in PAH using registry data.

Methods: From 2001 to 2005, WHO class II to IV patients were treated with bosentan or prostanoids.